Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.79 as of 2026-10-06T15:06:58.386Z.
Consensus retrieved: 2026-10-06T12:18:30.714Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:06:58.386Z.
Quote observation: 2026-10-06T15:05:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4494357cd0ca91989bcafb71c7abd0bcdd7911c73dc989e681ff47296789302f
Forward PE Ratio (17.79) = Dated Quote Price ($21.34) / Consensus Forward EPS ($1.20)
FORWARD PE RATIO
17.79
SECTOR MEDIAN · HEALTHCARE
19.04
median of 163 covered companies
CURRENT VS SECTOR MEDIAN
-6.57%
vs the sector median at left
Healthcare Services Group, Inc.
Market Cap
$1.46B
Forward PE Ratio
17.79
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Healthcare Services Group, Inc. (HCSG) | $1.46B | 17.79 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A |
| Certara, Inc. (CERT)vs › | $1.48B | 27.91 |
| GH Research PLC (GHRS)vs › | $1.48B | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 50.65 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.52B | 10.68 |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 7.94 |
Trailing P/E
12.5
reported TTM EPS
Forward P/E
17.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.20 implies -29.8% EPS decline vs the reported trailing $1.71.
At the dated quote price of $21.34, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.20 | $1.16 – $1.24 | 5 | 17.8x |
| 2027-12-31 | $1.23 | $1.19 – $1.26 | 5 | 17.3x |
| 2028-12-31 | $1.42 | $1.40 – $1.45 | 2 | 15.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
